Full Text
Estimating The Lifetime Clinical Risk/Benefits of Apixaban Versus Edoxaban In Non-Valvular Atrial Fibrillation

Abstract

Authors

H. Phatak P. Dorian T. Kongnakorn T. Lanitis X. Liu J. Mardekian J. Lawrence G. Lip

Back to Volume 18, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×